BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12901341)

  • 1. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelomonocytic leukemia: lost in classification?
    Bowen DT
    Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
    Elliott MA
    Best Pract Res Clin Haematol; 2006; 19(3):571-93. PubMed ID: 16781489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
    Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
    Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
    Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
    Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
    Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
    Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
    Chen YC; Chou JM; Letendre L; Li CY
    Am J Hematol; 2005 Aug; 79(4):329-31. PubMed ID: 16044436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The WHO classification of the myelodysplastic syndromes.
    Bain B
    Exp Oncol; 2004 Sep; 26(3):166-9. PubMed ID: 15494682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelomonocytic leukemia in the light of the WHO proposals.
    Germing U; Strupp C; Knipp S; Kuendgen A; Giagounidis A; Hildebrandt B; Aul C; Haas R; Gattermann N; Bennett JM
    Haematologica; 2007 Jul; 92(7):974-7. PubMed ID: 17606449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.